


TABLE COMPARING SEASONAL INFLUENZA VACCINES FOR 2010 SEASON

	FLUVAX®	VAXIGRIP®	INFLUVAC®												
Manufacturer:	CSL Biotherapies (NZ) Ltd	sanofi pasteur (NZ) Ltd, marketed by sanofi-aventis	Solvay Pharmaceuticals												
Influenza strains for 2010:	<ul style="list-style-type: none"> • A/ California /7/2009 (H1N1) - like virus • A/ Perth /16/2009 (H3N2) - like virus • B/ Brisbane /60/2008 - like viurs 														
Dosage:	<p>Immunisation Technical Forum (ITF) 2010</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Dose</th> <th>Number of doses</th> </tr> </thead> <tbody> <tr> <td>6-35 months</td> <td>0.25ml</td> <td>2*</td> </tr> <tr> <td>3-8 years</td> <td>0.5ml</td> <td>2*</td> </tr> <tr> <td>≥ 9 years</td> <td>0.5ml</td> <td>1</td> </tr> </tbody> </table>  <p>Influenza vaccine total dose = 0.5ml</p> <p>*Two doses separated by at least four weeks if vaccine is being used in children under 9 years of age (for 2010 only). Please note that this differs from the influenza vaccine data sheets and the Immunisation Handbook 2006. Younger children have a better immune response after two doses of the 2010 seasonal influenza vaccine because they are more likely to be immunologically naive to the H1N1 strain.</p>			Age	Dose	Number of doses	6-35 months	0.25ml	2*	3-8 years	0.5ml	2*	≥ 9 years	0.5ml	1
Age	Dose	Number of doses													
6-35 months	0.25ml	2*													
3-8 years	0.5ml	2*													
≥ 9 years	0.5ml	1													
Route of administration:	Intramuscular or deep subcutaneous injection														
Precautions needing further information: (See immunisation handbook 2006 for details)	<ul style="list-style-type: none"> • Those with immunodeficiency disorders may require two doses. • Those who have had Guillain-Barré syndrome (see the current Immunisation Handbook for recommendations). • Those allergic to neomycin, polymyxin B sulfate or gentamicin. • Reports have been published of patients on warfarin, theophylline, carbamazepine, phenobarbitone and phenytoin developing temporary toxicity following influenza immunisation. Prescribers are advised to be alert for signs of toxicity. However the possible risk of interactions should not preclude patients from being administered an influenza vaccine (Prescriber Update 2004;25(2):23-24 Potential for Flu Vaccine interaction exists). • Those with previous hypersensitivity to any component in the vaccine. 														
Components of special note:	<ul style="list-style-type: none"> • Neomycin • Polymyxin B sulfate 	<ul style="list-style-type: none"> • Neomycin 	<ul style="list-style-type: none"> • Gentamicin 												
Contraindications:	<ul style="list-style-type: none"> • Those who have had anaphylactic reaction (with respiratory and/or cardiac involvement) to hen eggs or chicken proteins, neomycin, polymyxin B sulfate, gentamicin or any other vaccine component. • Those with acute illness or fever over 38°C. 														
Presentation:	Pre-filled syringes: 0.5mL														
Storage:	Vaccines must be stored, protected from light, at +2°C to +8°C. DO NOT FREEZE. Discard if vaccine has been frozen.														
Phone regarding clinical information:	CSL Biotherapies: 0800 502 757	sanofi pasteur: 0800 PASTEUR (0800 727 838)	Solvay Pharmaceuticals: 0800 584 212												
Funding status	Fully funded for eligible groups														
Order from:	<p>Healthcare Logistics (HCL)</p> <ul style="list-style-type: none"> • Phone: 0508 425 358 • Fax: 0508 408 358 • www.hconline.co.nz 														

VAXIGRIP®, FLUVAX® and INFLUVAC® are Prescription Only Medicines. Please refer to manufacturers Data Sheet for further details or www.medsafe.govt.nz



0800 IMMUNE
(0800 466 863)
immune.org.nz